Welldoc said that its combination of real-time continuous glucose monitoring (CGM) and digital health impacts glucose control in type 2 diabetes.
Columbia, Maryland-based Welldoc presented data at the Conference on Advanced Technologies & Treatments for Diabetes (ATTD) from a study of real-time CGM and digital health in individuals with type 2 diabetes not treated with insulin. For all participants and subgroups examines, time in range and the glucose management indicator (GMI) improved significantly, demonstrating that the combination could improve type 2 diabetes management and glycemic control.
Get the full story at our sister site, Drug Delivery Business News.
